Gastrointestinal tract lymphomas

Extranodal Lymphomas: Pathology and Management

Volumn , Issue , 2008, Pages 233-242

  Neubauer, Andreas ^a   Zucca, Emanuele ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955822950     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (115)

1. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29: 252-60.
2. Otter R, Gerrits WB, vd Sandt MM, et al. Primary extranodal and nodal non-Hodgkin’s lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol 1989; 25: 1203-10.
3. Otter R, Willemze R. Extranodal non-Hodgkin’s lymphoma. Neth J Med 1988; 33: 49-51.
4. d’Amore F, Brincker M, Gronbaek K, et al. Non-Hodgkin’s lymphoma of the gastrointestinal tract:a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. J Clin Oncol 1994; 12: 1673-84.
5. Herrmann R, Panahon AM, Barcos MP, et al. Gastrointestinal involvement in non-Hodgkin’s lymphoma. Cancer 1980; 46: 215-22.
6. Hockey MS, Powell J, Crocker J, et al. Primary gastric lymphoma. Br J Surg 1987; 74: 483-7.
7. Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001: 1-351.
8. Shenkier TN, Connors JM. Primary extranodal non-Hodgkin’s lymphomas. In: Canellos GP, Lister TA, Young BD, eds. The Lymphomas, 2nd edn. Philadelphia: Saunders Elsevier, 2006: 325-47.
9. Nakamura S, Matsumoto T, Iida M, et al. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 2003; 97: 2462-73.
10. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19: 3861-73.
11. Severson RK, Davis S. Increasing incidence of primary gastric lymphoma. Cancer 1990; 66: 1283-7.
12. Doglioni C, Wotherspoon AC, Moschini A, et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992; 339: 834-5.
13. Gurney KA, Cartwright RA, Gilman EA. Descriptive epidemiology of gastrointestinal non-Hodgkin’s lymphoma in a population-based registry. Br J Cancer 1999; 79: 1929-34.
14. Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005; 128: S79-86.
15. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203-8.
16. Daum S, Weiss D, Hummel M, et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut 2001; 49: 804-12.
17. Wright DH, Jones DB, Clark H, et al. Is adult-onset coeliac disease due to a low-grade lymphoma of intraepithelial T lymphocytes?. Lancet 1991; 337: 1373-4.
18. Carbonnel F, Grollet-Bioul L, Brouet JC, et al. Are complicated forms of celiac disease cryptic T-cell lymphomas?. Blood 1998; 92: 3879-86.
19. Mearin ML, Catassi C, Brousse N, et al. European multi-centre study on coeliac disease and non-Hodgkin lymphoma. Eur J Gastroenterol Hepatol 2006; 18: 187-94.
20. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98: 51-60.
21. Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002; 287: 1413-19.
22. Smedby KE, Akerman M, Hildebrand H, et al. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005; 54: 54-9.
23. Krol AD, Hermans J, Kramer MH, et al. Gastric lymphomas compared with lymph node lymphomas in a population-based registry differ in stage distribution and dissemination patterns but not in patient survival. Cancer 1997; 79: 390-7.
24. Thieblemont C, Bastion Y, Berger F, et al. Mucosaassociated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997; 15: 1624-30.
25. Zucca E, Cavalli F. Gut lymphomas. Baillières Clin Haematol 1996; 9: 727-41.
26. Raderer M, Vorbeck F, Formanek M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000; 83: 454-7.
27. Radaszkiewicz T, Dragosics B, Bauer P. Gastro - intestinal malignant lymphomas of the mucosaassociated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992; 102: 1628-38.
28. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma -Results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19: 3874-83.
29. Cogliatti SB, Schmid U, Schumacher U, et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology 1991; 101: 1159-70.
30. Rohatiner A, d’Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5: 397-400.
31. Ruskone-Fourmestraux A, Dragosics B, Morgner A, et al. Paris staging system for primary gastrointestinal lymphomas. Gut 2003; 52: 912-13.
32. de Jong D, Aleman BM, Taal BG, et al. Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. Ann Oncol 1999; 10: 275-80.
33. Eidt S, Stolte M, Fischer R. Factors influencing lymph node infiltration in primary gastric malignant lymphoma of the mucosa-associated lymphoid tissue. Pathol Res Pract 1994; 190: 1077-81.
34. Taal BG, Boot H, van Heerde P, et al. Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept. Gut 1996; 39: 556-61.
35. Nakamura S, Matsumoto T, Suekane H, et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 2001; 48: 454-60.
36. Caletti G, Zinzani PL, Fusaroli P, et al. The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma. Aliment Pharmacol Ther 2002; 16: 1715-22.
37. Fischbach W, Goebeler-Kolve ME, Greiner A. Diagnostic accuracy of EUS in the local staging of primary gastric lymphoma: results of a prospective, multicenter study comparing EUS with histopathologic stage. Gastrointest Endosc 2002; 56: 696-700.
38. Fusaroli P, Buscarini E, Peyre S, et al. Interobserver agreement in staging gastric malt lymphoma by EUS. Gastrointest Endosc 2002; 55: 662-8.
39. Sackmann M, Morgner A, Rudolph B, et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted byendosonographic staging. MALT Lymphoma Study Group. Gastroenterology 1997; 113: 1087-90.
40. Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999; 131: 88-95.
41. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001; 48: 297-303.
42. Elstrom R, Guan L, Baker G, et al. Utility of FDGPET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-6.
43. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal Bcell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10: 1185-9.
44. Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005; 16: 473-80.
45. Ambrosini V, Rubello D, Castellucci P, et al. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nucl Med Rev Cent East Eur 2006; 9: 37-40.
46. Bertoni F, Sanna P, Tinguely M, et al. Association of gastric and Waldeyer’s ring lymphoma: a molecular study. Hematol Oncol 2000; 18: 15-19.
47. Thirlby RC. Gastrointestinal lymphoma: a surgical perspective. Oncology 1993; 7: 29-32.
48. Sano T. Treatment of primary gastric lymphoma:experience in the National Cancer Center Hospital, Tokyo. Recent Results Cancer Res 2000; 156: 104-7.
49. Gospodarowicz MK, Bush RS, Brown TC, et al. Curability of gastrointestinal lymphoma with combined surgery and radiation. Int J Radiat Oncol Biol Phys 1983; 9: 3-9.
50. Gospodarowicz MK, Sutcliffe SB, Clark RM, et al. Outcome analysis of localized gastrointestinal lymphoma treated with surgery and postoperative irradiation. Int J Radiat Oncol Biol Phys 1990; 19: 1351-5.
51. Gospodarowicz MK, Pintilie M, Tsang R, et al. Primary gastric lymphoma: brief overview of the recent Princess Margaret Hospital experience. Recent Results Cancer Res 2000; 156: 108-15.
52. Shepherd FA, Evans WK, Kutas G, et al. Chemotherapy following surgery for stages IE and IIE non-Hodgkin’s lymphoma of the gastrointestinal tract. J Clin Oncol 1988; 6: 253-60.
53. Maor MH, Velasquez WS, Fuller LM, et al. Stomach conservation in stages IE and IIE gastric non-Hodgkin’s lymphoma. J Clin Oncol 1990; 8: 266-71.
54. Salles G, Herbrecht R, Tilly H, et al. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d’Etude des Lymphomes Agressifs. Am J Med 1991; 90: 77-84.
55. Gobbi PG, Ghirardelli ML, Cavalli C, et al. The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas. Haematological 2000; 85: 372-80.
56. Gobbi PG, Dionigi P, Barbieri F, et al. The role of surgery in the multimodal treatment of primary gastric non-Hodgkin’s lymphomas. A report of 76 cases and review of the literature. Cancer 1990; 65: 2528-36.
57. Taal BG, Burgers JM, van Heerde P, et al. The clinical spectrum and treatment of primary non-Hodgkin’s lymphoma of the stomach [see comments]. Ann Oncol 1993; 4: 839-46.
58. Taal BG, Burgers JM. Primary non-Hodgkin’s lymphoma of the stomach: endoscopic diagnosis and the role of surgery. Scand J Gastroenterol 1991; 188: 33-7.
59. Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005; 23: 7050-9.
60. Popescu RA, Wotherspoon AC, Cunningham D, et al. Surgery plus chemotherapy or chemotherapy alone for primary intermediate- and high-grade gastric non-Hodgkin’s lymphoma: the Royal Marsden Hospital experience. Eur J Cancer 1999; 35: 928-34.
61. Ferreri AJ, Cordio S, Ponzoni M, et al. Non-surgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma. Leuk Lymphoma 1999; 33: 531-41.
62. Schmidt WP, Schmitz N, Sonnen R. Conservative management of gastric lymphoma: the treatment option of choice. Leuk Lymphoma 2004; 45: 1847-52.
63. Raderer M, Valencak J, Osterreicher C, et al. Chemotherapy for the treatment of patients with primary high grade gastric B-cell lymphoma of modified Ann Arbor Stages IE and IIE. Cancer 2000; 88: 1979-85.
64. Raderer M, Chott A, Drach J, et al. Chemotherapy for management of localised high-grade gastric Bcell lymphoma: how much is necessary?. Ann Oncol 2002; 13: 1094-8.
65. Aviles A, Nambo MJ, Neri N, et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg 2004; 240: 44-50.
66. Yoon SS, Coit DG, Portlock CS, et al. The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg 2004; 240: 28-37.
67. Tondini C, Giardini R, Bozzetti F, et al. Combined modality treatment for primary gastrointestinal non-Hodgkin’s lymphoma: the Milan Cancer Institute experience. Ann Oncol 1993; 4: 831-7.
68. Tondini C, Balzarotti M, Santoro A, et al. Initial chemotherapy for primary resectable large-cell lymphoma of the stomach. Ann Oncol 1997; 8: 497-9.
69. Sutcliffe SB, Gospodarowicz MK. Localized extranodal lymphomas. In: Keating A, Armitage J, Burnett A, et al, eds. Hematological Oncology. Cambridge:Cambridge University Press, 1992: 189-222.
70. Ibrahim EM, Ezzat AA, Raja MA, et al. Primary gastric non-Hodgkin’s lymphoma: clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma. Ann Oncol 1999; 10: 1441-9.
71. Ibrahim EM, Ezzat AA, El-Weshi AN, et al. Primary intestinal diffuse large B-cell non-Hodgkin’s lymphoma:clinical features, management, and prognosis of 66 patients. Ann Oncol 2001; 12: 53-8.
72. Cortelazzo S, Rossi A, Roggero F, et al. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 1999; 10: 1433-40.
73. Cortelazzo S, Rossi A, Oldani E, et al. The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Haematol 2002; 118: 218-28.
74. Gospodarowicz M, Tsang R. Radiation therapy of mucosa-associated lymphoid tissue (MALT) lymphomas. In: Zucca E, ed. MALT Lymphomas. Georgetown, TX: Landes Bioscience/Kluwer Academic, 2004: 104-29.
75. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21: 4157-64.
76. Wirth A, Teo A, Wittwer H, et al. Gastric irradiation for MALT lymphoma: reducing the target volume, fast! Australas Radiol 1999; 43: 87-90.
77. Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005; 97: 1345-53.
78. Montalban C, Santon A, Boixeda D, et al. Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication. Gut 2001; 49: 584-7.
79. Morgner A, Miehlke S, Fischbach W, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001; 19: 2041-8.
80. Zucca E, Bertoni F, Roggero E, et al. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000; 96: 410-19.
81. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4: 644-53.
82. Zucca E, Cavalli F. Are antibiotics the treatment of choice for gastric lymphoma?. Curr Hematol Rep 2004; 3: 11-16.
83. Bertoni F, Conconi A, Capella C, et al. Molecular follow- up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 2002; 99: 2541-4.
84. Thiede C, Wundisch T, Alpen B, et al. Persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 2001; 19: 1600-9.
85. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin’s lymphomas. Hematol Oncol 2005; 23: 10-17.
86. Schechter NR, Yahalom J. Low-grade MALT lymphoma of the stomach: a review of treatment options. Int J Radiat Oncol Biol Phys 2000; 46: 1093-103.
87. Bertoni F, Zucca E. State-of-the-art therapeutics:marginal-zone lymphoma. J Clin Oncol 2005; 23: 6415-20.
88. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 2005; 105: 2274-80.
89. Isaacson PG, Muller-Hermelink HK, Piris MA, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001: 157-60.
90. Lecuit M, Abachin E, Martin A, et al. Immuno - proliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350: 239-48.
91. Foss HD, Stein H. Pathology of intestinal lymphomas. Recent Results Cancer Res 2000; 156: 33-41.
92. Isaacson PG. Gastrointestinal lymphomas of T- and B-cell types. Mod Pathol 1999; 12: 151-8.
93. Gospodarowicz MK, Ferry JA, Cavalli F. Unique aspects of primary extranodal lymphomas. In:Mauch PM, Armitage JO, Harris NL, et al, eds. Non-Hodgkin’s Lymphomas. Philadelphia: Lippincott Williams & Wilkins, 2003: 685-707.
94. Domizio P, Owen RA, Shepherd NA, et al. Primary lymphoma of the small intestine: a clinicopathological study of 119 cases. Am J Surg Pathol 1993; 17: 429-42.
95. Morton JE, Leyland MJ, Vaughan Hudson G, et al. Primary gastrointestinal non-Hodgkin’s lymphoma:a review of 175 British National Lymphoma Investigation cases. Br J Cancer 1993; 67: 776-82.
96. d’Amore F, Christensen BE, Brincker H, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer 1991; 27: 1201-8.
97. Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkin’s lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997; 8: 727-37.
98. Hashimoto Y, Nakamura N, Kuze T, et al. Multiple lymphomatous polyposis of the gastrointestinal tractis a heterogenous group that includes mantle cell lymphoma and follicular lymphoma: analysis of somatic mutation of immunoglobulin heavy chain gene variable region. Hum Pathol 1999; 30: 581-7.
99. Isaacson PG, Wright DH, Ralfkiaer E, et al. Enteropathy-type T-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001: 208-9.
100. Silano M, Volta U, Vincenzi AD, et al. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci 2007 (Epub ahead of print Oct 13, 2007)
101. Howell WM, Leung ST, Jones DB, et al. HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Hum Immunol 1995; 43: 29-37.
102. Ferry JA. Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. Oncologist 2006; 11: 375-83.
103. Jelic TM, Barreta TM, Yu M, et al. Primary, extranodal, follicular non-Hodgkin lymphoma of the gallbladder:case report and a review of the literature. Leuk Lymphoma 2004; 45: 381-7.
104. Chiu KW, Changchien CS, Chen L, et al. Primary malignant lymphoma of common bile duct presenting as acute obstructive jaundice: report of a case. J Clin Gastroenterol 1995; 20: 259-61.
105. Gupta NM, Goenka MK, Jindal A, et al. Primary lymphoma of the esophagus. J Clin Gastroenterol 1996; 23: 203-6.
106. Dragosics B, Bauer P, Radaszkiewicz T. Primary gastrointestinal non-Hodgkin’s lymphomas. A retrospective clinicopathologic study of 150 cases. Cancer 1985; 55: 1060-73.
107. Liang R, Todd D, Chan TK, et al. Prognostic factors for primary gastrointestinal lymphoma. Hematol Oncol 1995; 13: 153-63.
108. Amer MH, el-Akkad S. Gastrointestinal lymphoma in adults: clinical features and management of 300 cases. Gastroenterology 1994; 106: 846-58.
109. Isikdogan A, Ayyildiz O, Buyukcelik A, et al. Non-Hodgkin’s lymphoma in southeast Turkey: clinicopathologic features of 490 cases. Ann Hematol 2004; 83: 265-9.
110. List AF, Greer JP, Cousar JC, et al. Non-Hodgkin’s lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. J Clin Oncol 1988; 6: 1125-33.
111. Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 1997; 26: 527-37.
112. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997; 89: 1350-5.
113. Nobre-Leitao C, Lage P, Cravo M, et al. Treatment of gastric MALT lymphoma by Helicobacter pylori eradication:a study controlled by endoscopic ultrasonography. Am J Gastroenterol 1998; 93: 732-6.
114. Montalban C, Santon A, Boixeda D, et al. Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up. Haematologica 2001; 86: 609-17.
115. Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018-24.